{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T14:34:58Z","timestamp":1785767698496,"version":"3.56.0"},"reference-count":40,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","license":[{"start":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:00:00Z","timestamp":1771545600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,2,20]]},"abstract":"<jats:p>\n                    Porocarcinoma is a rare malignant adnexal tumor arising from the eccrine sweat gland acrosyringium. The epidemiology, treatment patterns, and prognostic factors for this malignancy remain incompletely characterized due to its extreme rarity. This study aimed to provide a comprehensive population-based analysis of porocarcinoma in the United States. We retrospectively analyzed all porocarcinoma cases (ICD-O-3 code 8409\/3) from the Surveillance, Epidemiology, and End Results database diagnosed between 2000 and 2022. Patient demographics, tumor characteristics, treatment modalities, and survival outcomes were examined. Cancer-specific survival (CSS) was estimated using Kaplan\u2013Meier analysis, and prognostic factors were identified through Cox proportional hazards regression. A total of 953 patients were identified, representing the largest population-based porocarcinoma cohort to date. Mean age was 70.2\u2005\u00b1\u200515.9 years, with male predominance (55.5%). The lower extremity was the most common primary site (32.4%), followed by head\/neck (30.5%). The majority presented with localized disease (74.5%), while regional and distant disease accounted for 5.5% and 1.3%, respectively. Surgical treatment was performed in 83.5% of patients, predominantly wide excision (37.0%). Incidence increased over the study period, with 40.3% of cases diagnosed between 2016 and 2022. Five-year and 10-year CSS rates were 95.9% and 93.7%, respectively. Stage-specific 5-year CSS was 97.6% for localized, 76.6% for regional, and 47.6% for distant disease (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.001). On multivariate analysis, age (adjusted hazard ratio [aHR]\u2005=\u20051.042 per year,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.003), disease stage (aHR\u2005=\u20054.368 per level,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.001), and radiation therapy (aHR\u2005=\u20053.073,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.010) were independently associated with CSS. Wide excision demonstrated improved survival compared to no surgery on univariate analysis (HR\u2005=\u20050.349,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.026). Localized porocarcinoma treated surgically demonstrates excellent prognosis, with 5-year CSS exceeding 97%. Advanced disease confers significantly worse outcomes. Age and disease stage are independent prognostic factors. The increasing incidence underscores the need for continued surveillance and development of effective systemic therapies for advanced disease.\n                  <\/jats:p>","DOI":"10.1097\/md.0000000000047719","type":"journal-article","created":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T23:00:37Z","timestamp":1771628437000},"page":"e47719","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Epidemiology, treatment patterns, and survival outcomes of porocarcinoma: A population-based analysis"],"prefix":"10.1097","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4666-5118","authenticated-orcid":false,"given":"Akef","family":"Obeidat","sequence":"first","affiliation":[{"name":"College of Medicine, Alfaisal University, Riyadh, Saudi Arabia."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260523","first-page":"1431","article-title":"Eccrine porocarcinoma: a review of the literature.","volume":"13","author":"Tsiogka","year":"2023","journal-title":"Diagnostics (Basel, Switzerland)"},{"key":"R2-20260523","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1001\/archderm.1963.01590230105015","article-title":"Epidermotropic eccrine carcinoma. A case combining features of eccrine poroma and Paget\u2019s dermatosis.","volume":"88","author":"Pinkus","year":"1963","journal-title":"Arch Dermatol"},{"key":"R3-20260523","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1159\/000253989","article-title":"Oncogenic differentiation of the intraepidermal eccrine sweat duct: eccrine poroma, poroepithelioma and porocarcinoma.","volume":"138","author":"Mishima","year":"2009","journal-title":"Dermatologica"},{"key":"R4-20260523","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/his.15562","article-title":"WHO classification of skin tumours: key updates in the fifth edition.","volume":"88","author":"Goldman-L\u00e9vy","year":"2025","journal-title":"Histopathology"},{"key":"R6-20260523","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1097\/00000478-200106000-00002","article-title":"Eccrine porocarcinoma (malignant eccrine poroma): a clinicopathologic study of 69 cases.","volume":"25","author":"Robson","year":"2001","journal-title":"Am J Surg Pathol"},{"key":"R7-20260523","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1001\/archdermatol.2010.105","article-title":"Cutaneous appendageal carcinoma incidence and survival patterns in the United States: a population-based study.","volume":"146","author":"Blake","year":"2010","journal-title":"Arch Dermatol"},{"key":"R8-20260523","doi-asserted-by":"crossref","first-page":"5232","DOI":"10.3390\/cancers14215232","article-title":"Diagnosis and management of porocarcinoma.","volume":"14","author":"Miyamoto","year":"2022","journal-title":"Cancers (Basel)"},{"key":"R9-20260523","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1002\/mpo.1221","article-title":"Eccrine porocarcinoma in a child that evolved rapidly from an eccrine poroma.","volume":"37","author":"Valverde","year":"2001","journal-title":"Med Pediatr Oncol"},{"key":"R10-20260523","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.3390\/jcm11082185","article-title":"Head and neck porocarcinoma: SEER analysis of epidemiology and survival.","volume":"11","author":"Scampa","year":"2022","journal-title":"J Clin Med"},{"key":"R11-20260523","article-title":"Trends in the incidence of rare eyelid malignancies: a Surveillance, Epidemiology, and End Results-Based Study (2000\u20132021) [published online ahead of print December 11, 2025].","author":"Yaseen","journal-title":"Ocul Oncol Pathol"},{"key":"R12-20260523","doi-asserted-by":"crossref","first-page":"100129","DOI":"10.1016\/j.ajoint.2025.100129","article-title":"Age outweighs race in survival of sebaceous gland carcinoma of the eyelid: a 21-year SEER database analysis.","volume":"2","author":"Yaseen","year":"2025","journal-title":"AJO Int"},{"key":"R13-20260523","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1080\/01676830.2018.1505922","article-title":"Impact of clinicopathologic factors on survival in patients with sebaceous carcinoma of the eyelid \u2013 a population-based analysis.","volume":"38","author":"Lee","year":"2019","journal-title":"Orbit"},{"key":"R14-20260523","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/s41417-021-00347-z","article-title":"Whole-exome sequencing in eccrine porocarcinoma indicates promising therapeutic strategies.","volume":"29","author":"Denisova","year":"2022","journal-title":"Cancer Gene Ther"},{"key":"R15-20260523","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s13023-025-03586-7","article-title":"Whole-exome sequencing identifies distinct genomic aberrations in eccrine porocarcinomas and poromas.","volume":"20","author":"Puttonen","year":"2025","journal-title":"Orphanet J Rare Dis"},{"key":"R16-20260523","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.humpath.2015.12.015","article-title":"Porocarcinomas harbor recurrent HRAS-activating mutations and tumor suppressor inactivating mutations.","volume":"51","author":"Harms","year":"2016","journal-title":"Hum Pathol"},{"key":"R17-20260523","doi-asserted-by":"crossref","first-page":"3827","DOI":"10.1172\/JCI126185","article-title":"Recurrent YAP1-MAML2 and YAP1-NUTM1 fusions in poroma and porocarcinoma.","volume":"129","author":"Sekine","year":"2019","journal-title":"J Clin Invest"},{"key":"R18-20260523","first-page":"33","article-title":"Results of surgical treatment of patients with malignant eccrine poroma.","volume":"53","author":"Yazar","year":"2019","journal-title":"Sisli Etfal Hastan Tip Bul"},{"key":"R19-20260523","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1002\/hed.26178","article-title":"Eccrine porocarcinoma of the head and neck: meta-analysis of 120 cases.","volume":"42","author":"Le","year":"2020","journal-title":"Head Neck"},{"key":"R20-20260523","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/BF01600510","article-title":"A histopathological and ultrastructural study of eccrine porocarcinoma with special reference to its subtypes.","volume":"420","author":"Yamamoto","year":"1992","journal-title":"Virchows Arch A Pathol Anat Histopathol"},{"key":"R21-20260523","first-page":"2689","article-title":"Eccrine poroma: pathogenesis, new diagnostic tools and association with porocarcinoma \u2013 a review.","volume":"13","author":"Kyrmanidou","year":"2023","journal-title":"Diagnostics (Basel, Switzerland)"},{"key":"R22-20260523","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1111\/ijd.12997","article-title":"Treatment of eccrine porocarcinoma with Mohs micrographic surgery: a cases series and literature review.","volume":"54","author":"Tidwell","year":"2015","journal-title":"Int J Dermatol"},{"key":"R23-20260523","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1177\/229255030301100304","article-title":"Eccrine porocarcinoma: a case report and review of the literature.","volume":"11","author":"Lloyd","year":"2003","journal-title":"Can J Plast Surg"},{"key":"R24-20260523","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.circen.2015.12.006","article-title":"Multiple recurrent eccrine porocarcinoma with inguinal metastasis. A case report.","volume":"84","author":"Acosta-Arencibia","year":"2016","journal-title":"Cirug\u00eda y Cirujanos (English Edition)"},{"key":"R25-20260523","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/DSS.0000000000003652","article-title":"Epidemiology and survival of eccrine porocarcinoma by sex in the United States: a surveillance, epidemiology, and end results database analysis.","volume":"49","author":"Ragi","year":"2023","journal-title":"Dermatol Surg"},{"key":"R26-20260523","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/bjd.18874","article-title":"Demographics and outcomes of eccrine porocarcinoma: results from the national cancer database.","volume":"183","author":"Behbahani","year":"2020","journal-title":"Br J Dermatol"},{"key":"R27-20260523","doi-asserted-by":"crossref","first-page":"5529","DOI":"10.1038\/s41598-022-09490-5","article-title":"UV-induced local immunosuppression in the tumour microenvironment of eccrine porocarcinoma and poroma.","volume":"12","author":"Puttonen","year":"2022","journal-title":"Sci Rep"},{"key":"R28-20260523","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.amsu.2017.06.027","article-title":"Porocarcinoma; presentation and management, a meta-analysis of 453 cases.","volume":"20","author":"Salih","year":"2017","journal-title":"Ann Med Surg (Lond)"},{"key":"R29-20260523","doi-asserted-by":"crossref","first-page":"223","DOI":"10.5021\/ad.2020.32.3.223","article-title":"Eccrine porocarcinoma: a multicenter retrospective study with review of the literatures reported in Korea.","volume":"32","author":"Kim","year":"2020","journal-title":"Ann Dermatol"},{"key":"R30-20260523","doi-asserted-by":"crossref","first-page":"991","DOI":"10.2340\/00015555-3000","article-title":"Eccrine porocarcinoma of the skin is rising in incidence in the east of England.","volume":"98","author":"Goon","year":"2018","journal-title":"Acta Derm Venereol"},{"key":"R31-20260523","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1477-7819-9-32","article-title":"Metastatic eccrine porocarcinoma: report of a case and review of the literature.","volume":"9","author":"Marone","year":"2011","journal-title":"World J Surg Oncol"},{"key":"R32-20260523","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1097\/DSS.0000000000000382","article-title":"Eccrine porocarcinoma treated by Mohs micrographic surgery: over 6-year follow-up of 12 cases and literature review.","volume":"41","author":"Xu","year":"2015","journal-title":"Dermatol Surg"},{"key":"R33-20260523","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1097\/DSS.0000000000000286","article-title":"Mohs micrographic surgery for eccrine porocarcinoma: an update and review of the literature.","volume":"41","author":"Song","year":"2015","journal-title":"Dermatol Surg"},{"key":"R34-20260523","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1097\/DSS.0000000000001566","article-title":"Eccrine porocarcinoma: new insights and a systematic review of the literature.","volume":"44","author":"Nazemi","year":"2018","journal-title":"Dermatol Surg"},{"key":"R35-20260523","first-page":"1695","article-title":"The role of postoperative radiotherapy in eccrine porocarcinoma: a multidisciplinary systematic review.","volume":"26","author":"Fionda","year":"2022","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"R36-20260523","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1007\/s12032-025-02785-3","article-title":"Integration of immunotherapy and radiotherapy in a therapeutic algorithm for locally advanced squamous cell skin cancer.","volume":"42","author":"Koukourakis","year":"2025","journal-title":"Med Oncol"},{"key":"R37-20260523","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/j.1468-3083.2004.00949.x","article-title":"Antitumour activity of paclitaxel and interferon-alpha in a case of metastatic eccrine porocarcinoma.","volume":"18","author":"Gutermuth","year":"2004","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R38-20260523","first-page":"1227","article-title":"Metastatic eccrine porocarcinoma: a 5.6-year follow-up study of a patient treated with a combined therapeutic protocol.","volume":"29","author":"Gonz\u00e1lez-L\u00f3pez","year":"2003","journal-title":"Dermatol Surg"},{"key":"R39-20260523","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1111\/bjd.20604","article-title":"High tumour mutational burden and EGFR\/MAPK pathway activation are therapeutic targets in metastatic porocarcinoma.","volume":"185","author":"Westphal","year":"2021","journal-title":"Br J Dermatol"},{"key":"R40-20260523","first-page":"e20004","article-title":"Metastatic porocarcinoma effectively managed by pembrolizumab.","volume":"13","author":"Singh","year":"2021","journal-title":"Cureus"},{"key":"R41-20260523","doi-asserted-by":"crossref","first-page":"691","DOI":"10.2340\/00015555-3173","article-title":"Evaluation of sentinel lymph node biopsy for eccrine porocarcinoma.","volume":"99","author":"Tsunoda","year":"2019","journal-title":"Acta Derm Venereol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000047719","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T23:00:18Z","timestamp":1779577218000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000047719"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,20]]},"references-count":40,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000047719","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,20]]},"assertion":[{"value":"2025-12-02","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-28","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}